TERN 701
Alternative Names: HS-10382; TERN-701; TRN-000632Latest Information Update: 28 Jun 2025
At a glance
- Originator Terns Pharmaceuticals
- Developer Jiangsu Hansoh Pharmaceutical; Terns Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Bcr-Abl tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Chronic myeloid leukaemia
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(In the elderly, Second-line therapy or greater, In adults) in China (PO)
- 20 Mar 2025 Pharmacokinetics data from a phase I trial in healthy volunteers released by Tern Pharmaceuticals
- 03 Dec 2024 Efficacy, adverse events and pharmacokinetic data from the phase I CARDINAL trial in Chronic myeloid leukemia released by Terns Pharmaceuticals